Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies

Recruiting now · Not applicable

Conditions studied: Prostate Cancer

In brief

To study a novel biopsy needle system for performing transperineal prostate biopsy. Prostate biopsy remains the standard approach for prostate cancer detection. While pre-biopsy MRI allows for targeting of visible lesions, systemic or 'off target' samples are recommended due to the well-recognized risk of undegrading and under sampling with current commercially available needles. The SureCore plus single-use biopsy needle produces a more intact tissue core with a same caliber 18g needle with \~21% more tissue per core in pre-clinical studies. This research study will determine if a new biopsy needle designed to produce more robust tissue cores per sample can improve detection and characterization of prostate cancer.

Key facts

Study ID

NCT06907446

Run by

University of California, Davis

People needed

50

Starts

2025-05-01

Expected to finish

2027-12-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patient older than age of 18 undergoing prostate biopsy

You may not qualify if…

• Unable to consent
• Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives
• Prisoners

Where it is running

• UC Davis Departments of Urologic Oncology — Sacramento, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.